EYPT (EyePoint) Other Financing: $172.08 Mil (TTM As of Mar. 2026)


EYPT EyePoint Inc EYPT
34 GF Score
Price $14.29
GF Value $0.83
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is EyePoint Other Financing?

EyePoint EYPT +1.38% 34 Other Financing is $172.08 Mil as of Mar. 2026. GuruFocus rates EYPT with a GF Score™ of 34/100 and a GF Value™ of $0.83 (Significantly Overvalued). The stock has 7 warning signs investors should review.

EyePoint's Other Financing for the three months ended in Mar. 2026 was $-2.59 Mil.

EyePoint's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $172.08 Mil.

EyePoint Other Financing Historical Data

* Premium members only.

The historical data trend for EyePoint's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EyePoint Other Financing Chart

EyePoint Annual Data
Trend Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 -2.79 1.41 0.81 0.31

EyePoint Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.92 0.25 7.43 166.98 -2.59
EYPT
34GF Score
EyePoint Inc EYPT
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EyePoint Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $172.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $172.08 Mil mean?
EyePoint (EYPT) has a Other Financing of $172.08 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for EyePoint and its competitors.
Is EyePoint's Other Financing too high?
EyePoint's current Other Financing is $172.08 Mil. Overall, EyePoint has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does EyePoint's Other Financing compare to SPTX and CRVS?
EyePoint's Other Financing of $172.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for EyePoint and its competitors. EyePoint's current Other Financing is $172.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EyePoint stock overvalued right now?
Based on GuruFocus' analysis, EyePoint (EYPT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.83, compared to a current price of $14.29 — trading 1621.7% above its estimated fair value. The current Other Financing is $172.08 Mil. EyePoint's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For EyePoint (EYPT), the current Other Financing is $172.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EyePoint (EYPT) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of $14.29 is trading 1621.7% above its estimated GF Value™ of $0.83. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for EYPT:

  • Other Financing: $172.08 Mil
  • GF Value™: $0.83 vs. price of $14.29 (1621.7% above fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EYPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EyePoint Business Description

Other Exchanges PV3B:Germany
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
34GF Score

Get the complete analysis for EYPT

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.29
Price
$0.83
GF Value